FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 08/2023”. The Monitor is a month-to-month revealed overview of enterprise capital traits within the European Life Sciences sector.
As of the tip of August 2023 we establish the next present VC traits in Europe:
- In 2023, general Life Sciences funding has reached EUR 5,610m
- Biotech obtained 46% of the whole funding quantity (fixed in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotech
- Chemify (United Kingdom) has the best transaction quantity of EUR 32m in August, adopted by Bactolife (Denmark) EUR 30 and Lindus Well being (United Kingdom) EUR 16m
- The European Innovation Council Fund (Belgium) dominates the High 5 Traders (by deal quantity), adopted by Revival Healthcare Capital (United States) and Gilde Healthcare Companions (Netherlands)
- High 5 Offers exceed EUR 125m every, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the total report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.